Home
Contact Us
About Us
Advertise
Biotech
Finance
Tech News
Disclaimer
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
BioPharmaJournal
Home
Contact Us
About Us
Advertise
Biotech
Sorrento Therapeutics Inc (NASDAQ:SRNE) Reports Positive Results From Phase 1b Clinical…
Celsion Corporation (NASDAQ:CLSN) Presents A Poster Highlighting Its Phase I And…
Synthetic Biologics Inc (NYSE:SYN) begins Phase 1a Clinical Trial Of SYN-020…
Gritstone Oncology Inc (NASDAQ:GRTS) Begins Phase 1 Clinical Study Of COVID-19…
Timber Pharmaceuticals Inc (NYSE:TMBR) Receives ODD For TMB-003 From The US…
Finance
Hollywall Entertainment Inc (OTCMKTS:HWAL): Under-the-Radar NFT Star in the Making? (PLBY,…
GeoVax Labs (GOVX) surges on positive sentiment
Compass Pathways (CMPS) could lead psychedelic sector
Moderna Inc (NASDAQ:MRNA) Signs Deal With Baxter International Inc (NYSE:BAX) For…
Bitcoin Stocks for the Win (SQ, RIOT, ISWH, HVBTF)
Tech News
Tauriga Sciences Inc (OTCMKTS:TAUG) Could React on New Aegea Rapid Test…
Micro and Macro Tailwinds Converge for KULR
ISWH and the Rebirth of the Crypto Cycle
Disclaimer
Home
Tags
NASDAQ:HEPA
Tag: NASDAQ:HEPA
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) Announces Dosing Of First NASH Patient With...
admin
-
January 11, 2021
0
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) Announces CRV431 Study Results In Liver Disease
Gavins Felicity
-
December 17, 2020
0
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) Completes The Study Of CRV431
Matt Wade
-
September 11, 2020
0
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) Releases Early Stage Data For CRV431’s Research...
Ward Sport
-
July 17, 2020
0
.td-post-views{ display: none !important; }
